The present invention relates to lymphocytes, preferably that have been transinfected from dendritic cells with a bacterium, preferably CD4+ T cells, preferably Listeria monocytogenes, wherein said bacterium comprises a tumor peptide. It also relates to the use of lymphocytes for therapy and/or treatment of solid tumors, preferably melanoma, the kit or device that comprises same for this purpose. Furthermore, it also refers to the transinfection method thereof.
1. Transinfected lymphocyte with a bacterium comprising a tumor antigen wherein the transinfected lymphocyte comprises the tumor antigen in the major histocompatibility complex I (MHC-I). 2. Lymphocyte according to claim 1 wherein the lymphocyte is CD4+ T cell and/or B cell 3. Lymphocyte according to any of claims 1 or 2 wherein the bacterium is selected from the list consisting of: L. monocytogenes, Salmonella enterica, Mycobacterium bovis, Staphylococcus aureus and Escherichia coli. 4. Lymphocyte according to any of claims 1 to 3 wherein the transinfection is performed from an antigen presenting cell. 5. Lymphocyte according to claim 4 wherein the antigen presenting cell is a dendritic cell. 6. Lymphocyte according to any of claims 1 to 5 wherein the lymphocyte is heterologous or autologous. 7. Lymphocyte according to any of claims 1 to 6 wherein the lymphocyte is from a human. 8. Cell population comprising the lymphocyte according to any of claims 1 to 7. 9. Pharmaceutical composition comprising the lymphocyte according to any of claims 1 to 7 or the cell population according to claim 8. 10. Use of the lymphocyte according to any of claims 1 to 7 or of the cell population according to claim 8 for the manufacture of a medicament. 11. Use of the lymphocyte according to any of claims 1 to 7 or of the cell population according to claim 8 for the manufacture of a medicament for the prevention or treatment of tumor and/or stimulating the immune response against a tumor antigen. 26 12. Use according claim 11 wherein the tumor is selected from the list consisting of: melanoma, lymphoma, chronic lymphocytic leukemia, myeloma, breast, ovary, uterus, cervix, testis, prostate, colon, colorectal, pancreatic, stomach and gastrointestinal tumors, gastric cancer, liver tumor, kidney, bladder, mouth cancer, pharynx, larynx, esophagus, lung, thyroid, glioblastoma, glioma, sarcoma, encephalon, brain, neuroblastoma and marrow, head and neck blastoma, bone and connective tissue. 13. Kit or device comprising the lymphocyte according to any of claims 1 to 7 or the cell population according to claim 8. 14. Use of the kit or device according to claim 13 for prevention or treatment of tumor and/or stimulating the immune response against a tumor antigen. 15. Use according to claim 14 wherein the tumor is selected from the list consisting of: melanoma, lymphoma, chronic lymphocytic leukemia, myeloma, breast, ovary, uterus, cervix, testis, prostate, colon, colorectal, pancreatic, stomach and gastrointestinal tumors, gastric cancer, liver tumor, kidney, bladder, mouth cancer, pharynx, larynx, esophagus, lung, thyroid, glioblastoma, glioma, sarcoma, encephalon, brain, neuroblastoma and marrow, head and neck blastoma, bone and connective tissue. 16. In vitro method for transinfecting a lymphocyte comprising the following steps: a. Isolating an antigen-presenting cell and a lymphocyte from a biological sample; b. differentiating the antigen-presenting cell; c. infecting the antigen presenting cell of step (b) with a bacterium, where the bacterium comprises a tumor antigen; d. contacting the antigen-presenting cell infected in step (c) with the lymphocyte of step (a) at a temperature of 35-38 ° C for 24-72 hours to transinfecting it. 17. Method of claim 16 wherein it further comprises a step (e) for the selection of the transinfected lymphocyte of step (d). 18. Method of claim 16 or 17 wherein the bacterium is selected from the list consisting of: L. monocytogenes, Salmonella enterica, Mycobacterium bovis, Staphylococcus aureus and Escherichia coli. 27 19. Method according to any of claims 16 to 18 wherein the antigen presenting cell is a dendritic cell. 20. Method according to any of claims 16 to 19 wherein the lymphocyte is CD4+ T cell and/or B cell. 21 Method according to any of claims 16 to 20 wherein the lymphocyte is autologous or heterologous. 22. Method according to any of claims 16 to 21 wherein in step (d) the temperature is 37° C for 48 hours